Vitiligo Prevalence and Why It Isn't Cosmetic

Welcome back to another AJMC Stakeholder Summit series. In "Vitiligo Prevalence and Why It Isn't Cosmetic," moderator Susan Taylor, MD is joined by Iltefat Hamzavi, MD and Seemal Desai, MD, FAAD to open the conversation on vitiligo, starting with disease burden and prevalence.

Dr. Desai opens the clinical discussion by rejecting the idea that vitiligo is rare or purely cosmetic. He describes it as a T-cell-mediated, chronic inflammatory autoimmune disease that belongs in the same category as psoriasis, atopic dermatitis, and chronic hypertension. Citing a study his group published around World Vitiligo Day 2026, he puts United States prevalence at roughly 1.5% to 2%, a figure that mirrors registry data from the United Kingdom, France, Germany, and Italy. He notes that reliable data remain scarce for populations in Sub-Saharan Africa, Asia, and Latin America, and cites reported prevalence as high as 5% in parts of the Indian subcontinent.

Dr. Taylor raises a persistent problem: some insurers still treat vitiligo as cosmetic rather than medical. Dr. Desai counters that its cultural, social, and psychological stigma functions as a comorbidity in its own right, and that documented systemic associations include thyroid disease, type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, and cutaneous lupus. He describes treating patients with major depressive disease and suicidal ideation tied directly to their vitiligo, and argues payers need to recognize that burden when deciding what to cover. He points to a newly published severity-classification study, developed with international colleagues and appearing in JAMA Dermatology, that scores vitiligo on psychological impact as well as body-surface involvement.

Turning to diagnosis, Dr. Desai walks through the differential for early, hypopigmented vitiligo, which can mimic hypopigmented eczema, post-inflammatory hypopigmentation from trauma or burns, sarcoidosis, and autoimmune connective tissue disease. He stresses biopsy whenever the diagnosis is uncertain, since catching the disease in its hypopigmented phase, before melanocytes are fully lost, can prevent further depigmentation and guide earlier, more aggressive treatment with topical anti-inflammatories or phototherapy.

The next episode in this series, "Vitiligo Pathogenesis: How Autoimmunity Targets the Melanocyte," follows Dr. Hamzavi as he traces the autoimmune biology behind the disease.

This video was supported independently by Pfizer.